Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 927Neoplasms 612Breast Neoplasms 611Colorectal Neoplasms 458Neoplasm Metastasis 398Ovarian Neoplasms 333Prostatic Neoplasms 316Melanoma 316Lung Neoplasms 294Multiple Myeloma 293Recurrence 281Squamous Cell Carcinoma of Head and Neck 248Stomach Neoplasms 232Pancreatic Neoplasms 231Leukemia, Myeloid, Acute 224Triple Negative Breast Neoplasms 193Endometrial Neoplasms 190Carcinoma, Renal Cell 183Lymphoma, Non-Hodgkin 178Carcinoma, Hepatocellular 178Small Cell Lung Carcinoma 166Leukemia, Lymphocytic, Chronic, B-Cell 158Advanced Solid Tumors 158Lymphoma, Follicular 150Lymphoma, Large B-Cell, Diffuse 141Urinary Bladder Neoplasms 140Lymphoma 138Advanced Solid Tumor 137Uterine Cervical Neoplasms 136Head and Neck Neoplasms 134

Interventions

Cannabidiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Spasms, Infantile × 1 year × Clear all
NCT04485104 2025-10-31

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

Jazz Pharmaceuticals

Phase 3 Terminated
3 enrolled 28 charts

Tuberous Sclerosis 1, Tuberous Sclerosis 2, Epilepsy, Epilepsies, Myoclonic, Seizures, Spasms, Infantile, Tuberous Sclerosis, Lennox Gastaut Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡